Data-driven COVID-19 Vaccine Development for Janssen
The COVID-19 pandemic has spurred extensive research in vaccine development. However, Phase III vaccine trials’ success highly depends on future COVID-19 incidence rates at trial sites. To accurately predict these rates, we created DELPHI, a novel policy-driven and machine-learning powered epidemiological model. DELPHI has been the centerpiece of site selection for Ad26.COV2-S, the leading vaccine candidate from Janssen.
Team:
Dimitris Bertsimas, Massachusetts Institute of Technology
Michael Lingzhi Li, Massachusetts Institute of Technology
Omar Skali Lami, Massachusetts Institute of Technology
Hamza Tazi Bouardi, Massachusetts Institute of Technology
Ali Haddad-Sisakht, Dynamic Ideas LLC
Jennings Xu, Janssen Pharmaceuticals
Jose Zamalloa, Janssen Pharmaceuticals
Amir Hashemi, Janssen Pharmaceuticals
Ankit Lodha, Janssen Pharmaceuticals
Yuqi Shang, Janssen Pharmaceuticals
Kris Standish, Janssen Pharmaceuticals
Shi-hua Yu, Janssen Pharmaceuticals
Levon Demirdjian, Janssen Pharmaceuticals
Xiaoying Wu, Janssen Pharmaceuticals
Sid Jain, Janssen Pharmaceuticals
Najat Khan, Janssen Pharmaceuticals